Galecto Biotech AB receives its initial financing in a Seed round co-led by Merck Serono Ventures and Novo A/S

Lund, January 2, 2012

Galecto Biotech AB today announcd its formation of Galecto Biotech AB. Founded by a group of international top-level scientists and biotech executives, the company is supported by Novo A/S, Merck Serono Ventures and Forskarpatent. Galecto Biotech will develop modulators of galectins, initially focusing on novel galectin-3 inhibitors, which have demonstrated the potential to treat a range of debilitating diseases.

Read more